- By Bob Nellis
Mayo Clinic Confirms Genetic Predictor for Fuchs' Corneal Dystrophy
ROCHESTER, Minn. — May 4, 2012. Mayo Clinic and University of Oregon researchers have confirmed that a genetic factor called a repeating trinucleotide is a strong predictor of an individual's risk of developing the eye condition Fuchs' dystrophy. The findings were being presented today at the annual conference of the Association for Research in Vision and Ophthalmology in Orlando, Fla.
Fuchs' dystrophy is an eye condition that occurs when the cells at the back of the cornea deteriorate, causing fluid buildup resulting in swelling and cloudy vision. Fuchs' can be inherited. Until recently, the cause for most cases was unknown, but Mayo researchers showed a variation in the gene for transcription factor 4 (TCF4) was a major cause of Fuchs'.
The findings are based on an initial genome-wide association study that revealed a link between Fuchs' dystrophy and the TCF4 gene. Mayo researchers further defined the association with Fuchs' to be due to unusually long segments of repeated DNA nucleotides in the gene. In this case, three nucleotide residues (aka trinucleotide) repeat more than 40 times, some as high as several thousand repeats.
"Those long repeats of trinucleotides cause havoc, impacting the coding of the TCF4 protein," says lead researcher Keith Baratz, M.D., a Mayo Clinic ophthalmologist who will present at the conference. Characteristics of trinucleotide repeat diseases include later onset of the condition and progressive degeneration.
The study showed that a particular repeating trinucleotide, TGC in the TCF4 gene, is a strong predictor of disease. Researchers say that while Fuchs' dystrophy has other causes, TCF4 repeat expansion is a major cause of the condition in the patients in the Mayo study, accounting for about three-quarters of cases.
Mayo ophthalmologists will be involved in 24 presentations at the conference, which will include research findings on predictors of surgery in children with exotropia (outward eye deviation); symptoms of diplopia (double vision), and a new PC-based vision-screening test for children.
About Mayo Clinic:
Recognizing 150 years of serving humanity in 2014, Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit 150years.mayoclinic.org, http://www.mayoclinic.org and newsnetwork.mayoclinic.org.
Media Contact: Robert Nellis, 507-284-5005 (days), firstname.lastname@example.org